Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-003407
Filing Date
2022-02-08
Accepted
2022-02-08 06:07:46
Documents
48
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 791595
2 ex31-1.htm EX-31.1 17897
3 ex31-2.htm EX-31.2 17880
4 ex32-1.htm EX-32.1 6317
5 ex32-2.htm EX-32.2 6472
  Complete submission text file 0001493152-22-003407.txt   3659697

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nxen-20211231.xsd EX-101.SCH 31837
7 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nxen-20211231_cal.xml EX-101.CAL 29545
8 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nxen-20211231_def.xml EX-101.DEF 139206
9 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nxen-20211231_lab.xml EX-101.LAB 276152
10 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nxen-20211231_pre.xml EX-101.PRE 206673
42 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 425165
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 22599202
SIC: 2834 Pharmaceutical Preparations